NCE-1 Intelligence & Market Opportunity

Cobenfy

Xanomeline And Trospium Chloride

Antipsychotic

Oral Capsules

Cobenfy is used to treat schizophrenia. It is the first and only FDA-approved medication for schizophrenia. This drug works by activating muscarinic acetylcholine receptors, which are small proteins in the brain.

Approval Date

26-Sep-24

NCE-1 Date

26-Sep-28

NCE Date

26-Sep-29

Commercial snapshot

Market performance & projections

Revenue ($M)

155

CAGR (%)

93.34%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

362

2027

817

2028

1,419

2029

2,166

2030

2,920

2031

3,618

2032

4,321

Molecule profile

Details & specifications

Molecule

Xanomeline And Trospium Chloride

Innovator

BRISTOL-MYERS SQUIBB CO

Dosage Form

Oral Capsules

Strength

50 mg, 100 mg and 125 mg

Therapeutic Category

Antipsychotic

Usage

To treat schizophrenia

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets